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Ernst R. Berndt, Susan H. Busch, 
and Richard G. Frank 
It is not well to sneer at political economy in its relation to the 
insane poor. Whether we think it right or not, the question of 
cost has determined and will continue to determine their fate 
for weal or woe. 
-Asylum  Superintendent George Cook, 1866 
12.1  Introduction 
Much has been written in the last decade on broad trends in medical 
care spending in the United States. Although the most recent evidence is 
somewhat ambiguous, the apparent slowdown in the rate of  increase in 
aggregate health expenditures over the last five years has been welcomed 
by  many governments, employers, patients, and insurers. Relatively little 
attention, however, has focused on components of the change in expendi- 
tures. Is the trend change in medical care expenditures due to changes in 
price, quantity, quality, or a combination of all three? What has been the 
role of organizational change, such as the growth of managed care, relative 
to technological/pharmaceutical innovation, such as new medications, on 
expenditure trends? 
A standard procedure for economists analyzing changing expenditures 
over time is to employ official government price indexes, divide nominal 
expenditures by  such a price index, and thereby decompose expenditures 
Ernst R. Berndt is professor of applied economics at the Sloan School of Management of 
the Massachusetts Institute of Technology and director of the NBER’s Program on Techno- 
logical Progress and Productivity Measurement. Susan H. Busch is assistant professor in the 
Division of Health Policy and Administration of Yale Medical School. Richard G. Frank is 
professor of health economics at Harvard Medical School and a research associate of the 
National Bureau of Economic Research. 
The authors gratefully acknowledge research support from Eli Lilly and Company, the 
U.S. Bureau of Economic Analysis, National Science Foundation grant SBR-9511550, and 
National Institute of Mental Health grant MH43703. The authors are also grateful to Doug- 
las Cocks, Thomas Croghan, David Cutler, Dennis Fixler, Mark McClellan, Will Manning, 
Thomas McGuire, Joseph Newhouse, Charles Phelps, Jack Triplett, and seminar participants 
at the Carnegie Mellon-University of Pittsburgh Applied Micro Workshop for helpful com- 
ments on earlier drafts. 
463 464  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
into price and quantity components. Further analysis might then focus on 
factors affecting real quantity growth, such as productivity gains. 
In fact, the Bureau of Labor Statistics (BLS) medical consumer price 
index (CPI) is often used by analysts interested in undertaking such expen- 
diture decompositions. It is well known that such a practice is frequently 
inappropriate and misleading, for the medical CPI deals only with con- 
sumers’ direct out-of-pocket  payments  and does not  include payments 
from employers to insurers. 
A deeper issue, however, involves the conceptual foundations underlying 
the medical CPI and producer price indexes (PPIs). Although some revi- 
sions are gradually being implemented, the BLS price indexes are based 
largely on the repricing over time of a fixed bundle of inputs. For decades, 
health economists have argued that a more appropriate price index is one 
based on the entire episodic treatment of selected illnesses and conditions, 
incorporating technological and institutional innovations that change the 
mix  of inputs used to treat the condition, and including any effects on 
changed medical outcomes. 
Developing a price index in health care can be viewed in terms of the 
unique characteristics of the health services in question. Consider creating 
a price index for a good that displays the following features: 
Consumers pay only a portion of the gross price due to insurance. The 
insurance is associated with moral hazard resulting in “too much” use 
of the good. 
There have been dramatic technical change and great advances in the 
benefits offered by the good, yet the full range of benefits is difficult 
to measure. 
There is great variety in the forms that the good takes and consumers 
value those forms differently. 
The supply side of the market for the good has experienced funda- 
mental changes in its organization. 
The good is viewed as so important in some cases that the government 
compels people to use it. 
The treatment of  major depression, one of  the most prevalent  and dis- 
abling mental disorders, exhibits all of  the features listed above. In this 
paper we  report on the first three years of a research program aimed at 
measuring prices and output for the treatment of this important disease. 
The approach taken in this program of research builds on several recent 
efforts to construct price indexes for medical care. That recent research 
includes work by Cutler et al. (1998) that contrasts input price indexes for 
the treatment of heart attacks that rose by 6.7 percent per year over 1983- 
94, with an outcomes-adjusted index that takes into account a conservative 
valuation  for the extension of  life expectancy attributable to new  heart 
attack treatments and increases by  only 2.3 percent per year, implying a Treatment Price Indexes for Acute Phase Major Depression  465 
net bias of 4.4 percent annually. Focusing on a price index for cataract 
surgery, Shapiro, Shapiro, and Wilcox (chap. 10 in this volume) find that a 
CPI-like fixed-weight input-based index increases by a factor of about nine 
between 1969 and 1993, whereas their preferred alternative index incorpo- 
rating realized reductions in hospital lengths of stay, but ignoring any im- 
provements in the quality of medical outcomes, increases by only a factor 
of three, implying an annual differential of 4.6 percent. 
Because depression is a chronic recurring illness and mortality is not an 
endpoint, we  must rely on indirect methods of incorporating information 
on clinical effectiveness and outcomes. In our research we  have made use 
of results from the published clinical literature, and from official treatment 
guideline standards, to identify therapeutically similar treatment bundles 
that can then be linked and weighted to construct price indexes for treat- 
ment of specific forms of major depression. Preliminary results from this 
research have been published in Frank,  Berndt, and Busch (1999) and 
Frank, Busch, and Berndt (1998). 
In this paper we  consolidate our findings and extend our analysis con- 
siderably. Specifically, we  refine our definition of  eligible treatment  epi- 
sodes, develop new imputations for missing data, expand the set of treat- 
ment bundles from five to seven, and estimate hedonic price regressions. 
We  begin the paper with an overview of  current BLS procedures for 
constructing medical care price indexes, and then provide a background 
on the nature of and alternative treatments for acute phase major depres- 
sion. We outline features of the retrospective medical claims database from 
MEDSTAT, and then discuss our implementation of  treatment  episode 
definition and identification. We  then report on quantities and prices of 
the treatment bundles from 1991 to 1995, we  construct and interpret CPI- 
like and PPI-like aggregate price indexes, and we  comment on an initial 
analysis involving hedonic price procedures. We end the paper with a dis- 
cussion section, followed by  concluding remarks. 
12.2  Current Procedures for Measuring Medical Care Price Indexes 
In the U.S. context, it is useful to distinguish “supply” and “demand” 
prices for medical care. By  supply prices we  mean the total payments re- 
ceived by  health care providers for a particular  medical treatment, con- 
sisting of the sum of payments from health insurance plans (both private 
and  public)  plus  that  from  patients’  direct  out-of-pocket  payments 
(OOPPs). At this level of generality, our supply price concept relates to 
components of the Producer Price Index (PPI) published by the BLS. 
The demand  price  notion  we  employ  here is  the  consumers’ direct 
OOPPs, consisting of copayments and deductible cash payments made by 
the  patientkonsumer  to  providers for  a  particular  medical  treatment. 
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in the cost of treatment, while changes in the demand price can be traced 
both to changes in the cost of treatment and changes in benefit design. 
Our demand price concept relates to the medical care component of the 
BLS Consumer Price Index (CPI). As we  discuss below, the presence of 
insurance clouds the interpretation of the demand price index for depres- 
sion as a CPI. We also discuss important differences concerning the treat- 
ment of indirect consumer payments via, for example employees’ contribu- 
tions to employment-related health insurance. 
To associate the notion of a price index for treatment episodes of care 
with official price indexes published by  the BLS, we  now describe index 
number procedures currently employed by the BLS, beginning with its PPI.’ 
12.2.1 
The PPI “measures average changes in selling prices received by domes- 
tic producers for their output,” separately by industry.2 The PPI takes as 
its definition of an industry that based on the Standard Industrial Classi- 
fication (SIC) code, using four-digit SIC industries and their  aggregate^.^ 
Since its inception  in  1902, the PPI has focused rather  heavily on  the 
goods-producing sectors of the U.S. economy. In 1986, in recognition of 
the growing importance of services, the BLS gradually began to broaden 
the PPI’s scope of coverage in the services sectors, including medical care. 
Within each industry, the BLS calculates aggregate PPIs using a modi- 
fied  fixed-weight  Laspeyres  price  index  formula  over  individual  price 
quotes, where fixed weights are based  on value of shipments data. The 
primary price quote at the “cell index” level of disaggregation is “the net 
revenue accruing to a specified producing establishment from a specified 
kind of buyer for a specified product shipped under specified transactions 
terms on a specified day of the m~nth.”~  Although the BLS seeks transac- 
tion rather than list prices for its price quotes, the agency is well  aware 
that compliance by  firms is easier with list than with actual transaction 
prices. Participation by firms in the PPI is voluntary, with a “productive” 
compliance rate being about 63 percent in 1992 (Catron and Murphy 1996, 
13  1, table A-2). 
The BLS currently draws a sample of items for each industry on average 
about every seven years, and then reprices this fixed set of items monthly 
until an entirely new sample is drawn. In 1995 the BLS announced that 
for certain industries, particularly technologically dynamic ones such as 
pharmaceuticals and electronics in which seven-year time lags could yield 
a sample of products and services much older and quite unrepresentative 
BLS Procedures for Medical Care Related PPIs 
1, A more detailed discussion of the medical CPI and PPI data construction procedures 
2. U.S. Department of Labor, Bureau of Labor Statistics (1992), 140. 
3. See Triplett (1990) for economic issues involved in defining and aggregating industries 
4. U.S. Department of Labor, Bureau of Labor Statistics (1992), 141. 
is given in Berndt et al. (chap. 4 in this volume). 
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of market transactions, samples would be supplemented at one- or two- 
year intervals. 
For quite some time, the BLS has published PPIs for certain medical- 
related manufacturing industries, such as pharmaceuticals and diagnostic 
equipment. It is only recently, however, that the BLS has begun publishing 
PPIs for medical service industries such as hospital services and physician 
services. The BLS initiated a PPI for an aggregate of health services in 
December 1994, for offices and clinics of doctors of medicine in December 
1993, and for hospitals in aggregate and by type in December 1992. 
A central measurement issue in the construction of  medical price in- 
dexes involves the specification and implementation of a concept of indus- 
try output. For obvious reasons, the SIC structure is not well equipped to 
provide guidance to the BLS on what is the appropriate real output con- 
cept in medical care industries, nor on how this output quantity and out- 
put price can best be measured. 
An alternative source for guidance on implementation of a medical care 
output concept is provided by the Health Care Financing Administration 
(HCFA). In 1983 HCFA implemented a prospective payment schedule for 
inpatient hospital care whereby hospitals received a fixed payment for each 
Medicare patient admission, regardless of the amount or duration of ser- 
vices actually provided the patient. These Medicare prospective payment 
schedules distinguish treatments by twenty-four major diagnostic catego- 
ries, which are broken down further into 495 groupings of medical diagno- 
ses and surgical procedures, known as diagnostic related groups (DRGS).~ 
DRGs provide one possible output concept, but currently DRGs only 
measure output for inpatient hospital care; many outpatient commodities 
(e.g., prescription pharmaceuticals) and services are not included in the 
DRG system. Classification schemes used by  health care payers include 
version 4 of Current Procedural Terminology (CPT4) codes, a list contain- 
ing thousands of procedures for which physicians and hospitals can bill; 
these CPT4 codes can be  envisaged as inputs into the treatment  of  an 
illness or condition.6 A systematic structure of  diagnostic codes for ill- 
nesses and conditions is version 9 of the International Classification of Dis- 
eases (ICD-9).’ Relationships among ICD-9, CPT4, and DRG codes are 
multifaceted; a single DRG encompasses treatment of somewhat arbitrary 
aggregations of  distinct  ICD-9  diagnoses, alternative  combinations  of 
CPT4 codes can be used in the treatment of a particular ICD-9 diagnosis, 
and a given CPT4 procedure can be used in the treatment of various ICD-9 
diagnoses. The DRG system makes use of both ICD-9 and CPT4 coding 
5. For a recent list of DRGs, see Prospective Payment Assessment Commission (1995), 
appendix E. Note also that some private insurers and Medicaid programs make use of DRGs 
for purposes of hospital payment. 
6. For a discussion of CPT4, see American Medical Association (1990). 
7. ICD-9 codes are discussed and listed in U.S.  Department of Health and Human Services 
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systems. Other diagnostic-related  systems used  in  setting risk-adjusted 
capitation rates include the Ambulatory  Care Group algorithm (Weiner 
et  al.  1996) and the Hierarchical Coexisting Conditions model (Ellis et 
al. 1996). 
The BLS PPI program has initiated procedures for construction of med- 
ical  service PPIs at two rather  aggregate levels, physician  services and 
hospital services. In turn these encompass a variety of more detailed indus- 
tries, such as physician services from psychiatrists, general/family prac- 
titioners, internists, and hospital services from general medical and surgi- 
cal hospitals, psychiatric hospitals, and specialty nonpsychiatric hospitals. 
With respect to physician services, based on a sampling universe of all 
physician  practices  in  the United  States, the BLS constructs  a sample 
frame of physician practice units. From this sample unit, the BLS ran- 
domly chooses a bill that measures the net price paid to the practice for 
the entire set of  services and procedures provided during an office visit, 
distinguished by payer type. The physician’s output from this visit is repre- 
sented by the content of the patient’s bill, including CPT codes associated 
with that visit, and is related to a particular ICD-9 diagnosis. Given this 
sample bill, the BLS contacts the physician practice unit each month and 
asks it to reprice what the current net transaction prices would be for that 
particular fixed bundle/payer of services. Since the organization of physi- 
cian practices has undergone considerable upheaval and consolidation in 
the last few years, however, sample attrition in the BLS physician services 
PPI has been considerable, and maintaining a sufficiently large response 
rate for repricing has proven to be difficult.* 
The hospital services PPI measures net prices paid to hospitals for the 
entire bundle of services received during a hospital stay associated with a 
particular ICD-9 diagnosis, given the payer type. Hospital output is repre- 
sented by  the content of  a patient’s bill, including all charges for room, 
medical supplies, drugs, and ancillary services provided the patient during 
a single hospital stay. 
The sampling universe for the hospital  services PPI is  taken from the 
American Hospital Association, stratified by hospital size, public versus 
private ownership, and type of medical specialty. Once a hospital is identi- 
fied as a sample unit, the BLS chooses a fixed subset of DRGs, and each 
hospital  is  then asked on a monthly basis to report on net transaction 
prices of a single representative patient bill (typically the last patient bill 
on file for that DRG). Because the identical treatment bundle is not always 
observed in subsequent months, BLS reporters construct subsequent ficti- 
tious DRG bundle prices by repricing the identical  input^.^ 
8. For further discussion, see Fixler and Ginsburg (1997). 
9. For further details, see Catron and Murphy (1996),  Fixler and Ginsburg (1997), and 
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It is worth noting that with both the physician services and hospital 
services PPIs, BLS use of fixed itemized components for obtaining price 
quotes does not capture major input substitution of treatment for a condi- 
tion, such as the changing mix of psychotherapy and psychotherapeutic 
drugs used  for the  treatment  of  acute phase  depression. Such a zero- 
substitutability definition of  physician and hospital output leads to the 
existence of a substitution bias, but that bias is of course not confined to 
medical PPIs, for it pervades the entire fixed-weight Laspeyres price index 
computational procedures. 
Finally, for our purposes it is also useful to note that the BLS publishes 
a PPI for prescription pharmaceuticals. Although pricing the output of 
prescription pharmaceuticals presents some particularly interesting issues 
involving treatment of generic drugs and of quality improvements in new 
products, those issues are beyond the scope of this paper.‘O 
12.2.2 
According to the BLS, the CPI is “a measure of the average change in 
the prices paid by  urban consumers for a fixed market basket of  goods 
and services.”  l1 Based on data from its Consumer Expenditure Surveys 
(CEX), the BLS identifies and defines a fixed “market basket” of  goods, 
employing a classification system known as the item structure, which is 
updated  approximately every ten years. In January  1998 the BLS intro- 
duced its most  recent major  item structure and  fixed weight  revisions, 
based on the 1993-95  CEX; from January 1987 until January 1998, fixed 
weights had been based on the 1982-84  CEX. 
In contrast  to the BLS’s  recently initiated medical PPI program, the 
medical CPI has been published regularly since 1935.12  Currently the BLS 
publishes a monthly aggregate medical care CPI (MCPI), subindexes for 
medical care commodities and medical care services, as well  as for pre- 
scription drugs and medical supplies, nonprescription drugs and medical 
supplies, physician services, hospital and related services, and health in- 
surance.  Each  of  these  medical  related  CPIs  is  based  on  consumers’ 
OOPPs, and thereby excludes all medical payments by  governments, as 
well as employers’ contributions to employee health insurance; only medi- 
cal  OOPPs plus that  portion  of  third-party  insurance paid  for  out-of- 
pocket by employees is included within the scope of the MCPI. Thus, al- 
though national health spending in 1996 constituted 13.6 percent of GDP, 
the total weight given medical care items in the CPI in  1997 is  only 5.4 
percent.’? 
BLS Procedures for Medical Care Related CPIs 
10. For  further discussion, see Berndt, Cockburn, and Griliches  (1996), Griliches and 
11. U.S. Department of  Labor, Bureau of  Labor Statistics (1992), 176. 
12. For historical discussions, see Langford (1957) and Getzen (1992). 
13. Levit et al. (1998); Ford and Ginsburg (1997). 
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Recently the medical CPI has introduced a number of changes, some of 
which are similar to those implemented several years earlier in the PPI. 
Until at least  1990, in most cases the MCPI priced  specific input items 
at list prices (e.g., “chargemaster” fees for x-rays, laboratory tests, and 
physicians’ office visits) rather than at the average actual transaction price 
for treatment of, say, a child’s forearm fracture to a managed care organi- 
zation obtaining a hospital di~count.’~  Since 1993 the BLS has attempted 
to obtain hospital transaction rather than list prices, but through  1996, 
efforts “yielded slow progress to date” (Cardenas  1996b, 40). Beginning 
with the January 1998 major revisions, more aggressive efforts have been 
made to obtain actual hospital prices by  payer, but  information  is not 
yet available on the composition and nature of hospital quotes now being 
obtained. While DRG hospital quotes have been considered for use in the 
MCPI, the BLS is instead contemplating pricing “package” treatments, 
consisting of  “highly standardized and tightly defined components and 
risk factors” for conditions such as appendectomies, tonsillectomies, and 
cataract  surgery (Cardenas  1996b, 40). Details on  how  such treatment 
packages would be defined have not been released. Finally, while revisions 
involving hospital service components of the MCPI have been announced, 
the BLS has not yet published comparable information on revisions to the 
physician service components of the MCPI.I5 
12.2.3  BLS Procedures for Pricing Medical Treatments: Comments 
For  some time  now,  health  economists  and government  statisticians 
have pointed to directions toward which the pricing of medical care ser- 
vices should move. Here we briefly summarize several of the directions sug- 
gested by  this literature. First, as early as 1962 Anne Scitovsky proposed 
“an index which would show changes, not in the costs of such items of 
medical care such as drugs, physicians’ visits, and hospital rooms, but in 
the average costs of the complete treatment of individual illnesses such as, 
for example, pneumonia, appendictis, or measles.”’6  In Scitovsky (1  967), 
this treatment episode approach was implemented on an illustrative basis 
for five medical conditions. Discussions of shortcomings and biases inher- 
ent in the BLS MCPI approach, and of the preference for the treatment 
episode approach to medical price measurement, have appeared steadily 
since 1967; see, for example, the chapter “Measuring Changes in the Price 
of Medical Care” in various editions of the well-known health economics 
textbook by Paul Feldstein (1979, 1983, 1988) and the Baxter Foundation 
Prize address by Joseph Newhouse (1989). 
Second, experts agree, the measurement of changes in the price of medi- 
14. See, for example, Armknecht and Ginsburg (1992) and Cardenas (1996a, 1996b). 
15. For a discussion of  the pricing of  prescription pharmaceuticals in the MCPI, and 
treatment of generic drugs, see Armknecht, Moulton, and Stewart (1994), and U.S. Depart- 
ment of Labor, Bureau of Labor Statistics (1995). 
16. Scitovsky (1964); also see Scitovsky (1967). Treatment Price Indexes for Acute Phase Major Depression  471 
cal services should incorporate major quality changes, such as those in- 
volving adjustments for improvements in health care outcomes. In 1996, 
for example, Paul Armknecht noted that “A  new dimension needs to be 
included in the pricing of medical services that includes outcomes, so that 
if  cancer treatment results in improved survival rates, this is reflected in 
the index” (33).  The Boskin Commission final report went further, assert- 
ing that “we strongly endorse a move in the CPI away from the pricing of 
health care inputs to an attempt to price medical care outcomes” (U.S. 
Senate Finance Committee 1996, 60). Although incorporation of quality 
and outcomes changes into medical price indexes presents some significant 
conceptual challengesJ7  and implementation difficulties, it is clear that fail- 
ing to address these aspects is likely to result in price measures that are 
unreliable and inaccurate. 
Third, use of fixed weights over extended periods such as ten to twelve 
years in constructing sub- and aggregate price indexes is particularly inap- 
propriate in the medical care sector, where both institutional and techno- 
logical changes are rapidly occurring. Note that the frequency with which 
fixed weights are updated is distinct from the issue of which index number 
formula (e.g., Laspeyres, Paasche, or Tornqvist approximation to the Divi- 
sia) is preferable. For the rapidly changing medical care sector, decennial 
updates of fixed weights with old weights being fifteen years out of date 
before the new revision occurs (i.e., use of 1982-84 CEX weights through 
December  1997) results in price indexes whose accuracy and reliability 
can legitimately be called into question. 
In the research reported here, we extend previous research aimed at con- 
structing CPI- and PPI-like medical price indexes that deal with prices of 
treatment episodes rather than prices of discrete inputs, that are based on 
transaction rather than list prices, that take quality changes and expected 
outcomes into account, and that employ more current expenditure weights 
in the aggregation computations, Before describing the components of this 
research, however, we  digress to discuss the illness whose treatment price 
we measure, namely, acute phase major depression. 
12.3  The Nature and Prevalence of Major Depression 
Depression is commonly characterized by melancholy, diminished inter- 
est or pleasure in all or most activities, sleep disorders, and feelings of 
worthlessness. In order for a patient’s condition to be considered an epi- 
sode of major depression, a clinician must determine that a very specific 
set of clinical criteria have been met. According to the fourth edition of the 
Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric 
Association (APA), major depression is diagnosed when the following is 
observed: 
17. See, for example, the discussion between Gilbert (1961, 1962) and Griliches (1962). 472  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
The presence of one of the first two symptoms, as well as at least five of 
nine total symptoms. The symptoms must be present most of the day 
almost every day, for at least two weeks. The symptoms include: 
1) depressed mood most of the day nearly every day; 
2)  markedly diminished interest or pleasure in almost all activities 
3)  significant weight loss/gain; 
4)  insomnia/hypersomnia; 
5)  psychomotor agitatiodretardation; 
6) feelings of worthlessness (guilt); 
7)  fatigue; 
8) impaired concentration (indecisiveness); and 
9)  recurrent thoughts of death or suicide. (APA 1994, 161) 
most of the day; 
Two dimensions of depression involve its persistence. A single episode 
of the illness is self-explanatory given the above diagnostic criteria. A re- 
current depression is defined by  two or more major depressive episodes 
each separated by at least eight weeks of return to usual functioning (APA 
1993). Episodes of illness come and go, last from several weeks to several 
months, and are followed by periods of relatively normal mood and behav- 
ior.  Untreated,  the  average  depressive episode  lasts  from  four  to  six 
months. Although the vast majority of individuals who experience an epi- 
sode of major depression return to their original level of functioning, be- 
tween 20 and 35 percent experience persistent symptoms; when these per- 
sistent symptoms last for twenty-four months or longer, these cases are 
referred to as chronic depression.'*  Approximately 50 percent of all people 
having a depressive episode can be expected to have a recurrence, usually 
within two or three years. Once an individual has a second episode, addi- 
tional recurrence is 70 percent likely (APA 1993). The lifetime average for 
depressive episodes is five to seven, but as many as forty episodes have 
been reported (Papolos and Papolos 1992, 7). 
A number of studies have shown that depression has similar or greater 
functional  impairments  than  those  attributed  to  other  episodic  and 
chronic medical illnesses.'y Episodes of depression can be classified ac- 
cording to severity: mild, moderate, or severe. Mild depression typically 
involves the minimum number of symptoms required to meet clinical cri- 
teria and minor functional impairment. Moderately  severe episodes are 
characterized by an excess in symptoms above the minimum to meet clini- 
cal criteria and by greater degrees of functional impairment. Severe major 
depression involves a number of excess symptoms above the minimum and 
significant degrees of functional impairment including the ability to work 
or conduct usual activities. 
Epidemiological research indicates that in the early 1990s, 10.3 percent 
18. See Keller et al. (1984), and Keller, Lavori, Rice, et al. (1986). 
19. See, for example, Broadbent et al. (1990); Wells et al. (1989); Hays et al. (1995). Treatment Price Indexes for Acute Phase Major Depression  473 
of the U.S. population met the criteria for major depression at some time 
during a twelve-month period (Kessler et al. 1994). Depression is often 
accompanied by  other forms of ill health, such as anxiety, eating disor- 
ders, substance abuse, or other medical conditions (Kendler et al. 1995). 
Although the reasons are still not well understood, women-particularly 
women under age twenty-five-are  much more likely to suffer from de- 
pression than are men; the relative lifetime female/male prevalence rate is 
about 1.7. Rates of recurrence and chronicity for major depression appear 
to be no different for women and men (Kessler et al. 1993). 
12.4  Alternative Treatments for Acute Phase Major Depression 
The acute phase of major depression is typically defined as the stabiliza- 
tion of most acute symptoms. In practice, standards of care typically iden- 
tify the acute phase as occurring over a twelve-week period. In this re- 
search we  allow protocol levels of acute phase treatment to occur over a 
six-month period to recognize that actual practice departs from the con- 
trolled environment of efficacy research. In clinical practice, continuation 
therapy frequently follows on acute phase treatment in hopes of preventing 
relapse. If a recurrent episode of major depression occurs, maintenance 
treatments are often initiated to prevent further recurrences (Kupfer 199  1). 
Given the information available in claims data, distinguishing between 
acute and continuation phase treatment is difficult. We employ acute phase 
standards of care to establish expected outcomes, but in our empirical 
implementation we undoubtedly will mix acute and other phases of care. 
Clinical research on the continuation phase of treatment is less developed, 
and definitive protocols have not been as widely adopted in many clinical 
settings. 
12.4.1  Recent Developments in Psychotherapy 
and Antidepressant Medication 
Treatments for acute phase major depression have advanced consider- 
ably during the last two decades. In the area of psychotherapy, a variety 
of new techniques has expanded treatment options well beyond traditional 
psychodynamic  or  psychoanalytic  approaches.  Interpersonal  therapy 
(IPT), behavior therapy (BT), family therapy, and cognitive behavior ther- 
apy (CBT) are all relatively new. Evidence from controlled clinical trials 
suggests that when applied as the single mode of treatment for less severe 
forms of acute phase major  depression, each of these therapies reduces 
depressive symptoms. Moreover, relative to antidepressant medication as 
the sole treatment, each has generally been shown to perform at compa- 
rable levels of efficacy and to have similar outcomes.20 
20. See Beck et al. (1979), Elkin et al. (1989), Frank et al. (1990), Kupfer et al. (1992), and 
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Extraordinary advances have been achieved in the last two decades in 
the area of antidepressant medication. Although very recent developments 
expand the therapy  set even further, over the  1991-95  period examined 
here three general classes of antidepressant medications were employed. 
These are (1) cyclic antidepressants that include the widely used tricyclic 
antidepressants (TCAs) and a number of lesser-known drugs such as tra- 
zodone; (2) selective serotonin-reuptake inhibitors (SSRIs), which include 
brand  name drugs such as Prozac, Zoloft, Paxil, and LUVOX;~'  and (3) 
monoamine oxidase (MAO) inhibitors which, due to considerable side ef- 
fects and dangerous interactions, are generally used only for patients resis- 
tant to other forms of treatment. 
Newer SSRIs offer some distinct advantages over older TCAs, although 
in randomized controlled trials clinical efficacy rates are similar. SSRIs are 
associated with lower risk of overdose, and reduced levels and numbers of 
side effects. Important side effects frequently associated  with TCAs in- 
clude drowsiness, dry mouth, impaired ability to concentrate, seizures, and 
weight gain.2z  The side effects most  prominently associated with use of 
SSRIs relate to sexual dysfunction (particularly for males) and anxiety. 
The advantages  of SSRIs come at a significantly higher pecuniary cost 
than most TCAs. 
Psychotherapeutic interventions  have frequently been combined  with 
antidepressant medication  as a combination strategy for treating major 
depression.  The  specific interventions  that  have  been  most  intensively 
studied are the use  of  TCAs in combination with either IPT, BT,  or a 
general unspecified form of short-term psychotherapy. To date, no clinical 
studies have been  reported in the literature which  systematically assess 
the combination of the newer SSRIs and psychotherapy.2i It is generally 
presumed, however, that such combinations will be at least as efficacious 
as the combination of TCAs and psychotherapy. 
Finally, electroconvulsive therapy (ECT) is an effective treatment, but 
ECT is typically limited to rather special circumstances when the patient's 
depression is severe and is complicated by a number of other psychiatric 
symptoms including psychosis, catatonic stupor, or high risk of suicide. 
In the analysis reported below, we  focus on outpatient treatments for 
major depression; these constitute the vast majority of treatment episodes 
(75 to 80 percent). We do this for several reasons. First, inpatient claims 
data typically do not contain information on the drugs prescribed for treat- 
21.  Recent  variations  slightly distinct from the SSRIs include  the brand  name drugs 
Effexor, Serzone, and Remeron. 
22. Considerable variation exists in side effects among the TCAs; see Berndt, Cockburn, 
and Griliches (1996, 142-43,  table 1) for details. 
23. Using MEDSTAT retrospective claims data, Croghan et al. (1999) provide evidence 
suggesting that the combination of SSRIs and psychotherapy is more effective than psycho- 
therapy alone in patients receiving continuous treatment. For a discussion of related SSRI- 
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ment; thus characterizations of inpatient care are inherently inc~mplete.~~ 
Second, because of other incomplete information regarding illness severity 
and comorbid conditions, it is difficult to use administrative claims data 
to characterize fully an illness diagnosis, and therefore to make judgments 
about the appropriate use of hospital services for treating major depres- 
sion. Third, few clinical trials specifically address inpatient treatment for 
major depression, making it difficult to assign outcomes to treatments. 
Finally, because there was considerable evidence of  overuse of  hospital 
services in the aggregate during the late 1980s and early 199Os, the inclu- 
sion of hospital services in our 1991 base year could make interpretation 
of price changes troublesome.2s  This strategy of limiting severity of cases 
by excluding individuals hospitalized for treatment of depression is likely 
to be  only partly successful. During the  1990s there were  a substantial 
reduction in inpatient psychiatric admissions and in the length of stay for 
hospitalized cases. The implication of this is that the population of people 
treated only on an outpatient basis may be getting sicker over time. 
In our analysis, we  therefore focus on the use of various antidepressant 
medications alone, several forms of psychotherapy alone, and several drug- 
psychotherapy  combination  treatments.  Because  of  very  small  sample 
sizes, we  do not incorporate treatment involving ECT or the MA0 inhib- 
itors. 
12.4.2 
We  now provide a brief summary of research results comparing the ef- 
ficacy of alternative treatments for depression of varying severity. We  di- 
vide depression severity into two classes: severe and less severe (hereafter, 
mild). We  have  reviewed approximately thirty major clinical trials and 
meta-analyses from the clinical literature on comparative efficacy of acute 
phase treatments (Busch, Frank, and Berndt 1996). This literature points 
to several key conclusions. 
First, psychotherapies of all kinds have been shown to result in superior 
outcomes compared  to no  treatment.  When  compared amongst  them- 
selves, the different forms of psychotherapy appear to have no significant 
differences in outcomes.26 
Second, for  less  severe  forms  of  depression,  psychotherapies alone, 
TCAs with medical management, and SSRIs with medical management 
appear  to produce comparable outcomes. Each of  these therapies pro- 
duced significantly better outcomes than placebo treatments. Versions of 
these results have been reported in numerous large treatment trials and by 
Results from Comparative Efficacy Studies 
24. A  significant portion  of  inpatient  episodes have unspecified outpatient  follow-up, 
25. For a discussion, see Mechanic (1989) and McGuire (1989). 
26. The AHCPR Depression Guidelines Panel (U.S. Department of  Health and Human 
thereby limiting that avenue for identifying treatments. 
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meta-analyses of smaller clinical trials. Combination treatments with these 
as components also generate equivalent levels of efficacy for less severe 
forms of depression. 
Third, for more severe forms of depression, the bulk  of  the evidence 
suggests that TCAs alone, SSRIs alone, and combinations of drugs and 
psychotherapy have comparable levels of efficacy, and each results in supe- 
rior outcomes compared to psychotherapy alone. Recently some evidence 
has emerged  showing  some  extra  improvement  from  the  combination 
treatments relative to medication alone (APA 1993). We believe it is pre- 
mature to conclude that combination treatments offer significantly higher 
levels of efficacy than do antidepressant medications alone (or with medi- 
cal management, as is typically the case). 
Based on these observations from the literature, we  view all the major 
treatment technologies as offering comparable expected outcomes for the 
average care of less severe acute phase depression. For severe depression, 
we view TCAs and SSRIs alone as  comparable to each other and to combi- 
nations of TCAs and SSRIs with psychotherapy. 
12.5  Identifying Comparable Treatment Bundles from Claims Data 
The results from our review of the clinical trials literature enable us to 
develop a set of treatment “bundles” that group together therapeutically 
similar treatments of a specific form of major depression. This identifica- 
tion of treatment bundles that result in similar expected health outcomes 
is a crucial step in the construction of medical treatment price indexes that 
take expected outcomes into account. The implicit assumption we  adopt 
here is that obtaining therapeutically similar outcomes from alternative 
treatments provides a useful approximation to achieving similar expected 
utility levels.27 
12.5.1  The MEDSTAT Data 
To identify empirically comparable treatment bundles for acute phase 
major depression, we employ a data set consisting of retrospective insur- 
ance claims from four large self-insured employers that offered twenty-five 
health plans to 428,168 employees and their dependents for the years 1991 
through 1995. The data were obtained from MEDSTAT, Inc., and contain 
information on prescription drug claims, inpatient hospital treatment, out- 
patient visits, ICD-9 diagnoses, CPT4 procedures, and the demographic 
characteristics of all covered individuals. The health  benefits offered to 
27. We recognize this is only an approximation. This is particularly the case for depression, 
where the constellation of side effects across treatment can vary significantly and can lead to 
differential patient compliance and patient preferences between the SSRIs and TCAs. See 
Crown et al. (1996) and Wilde and Benfield (1998) for evidence on differential TCA-SSRI 
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enrollees in this database are quite generous relative to the general market 
for private health insurance in the United States. 
During the five years we  observed, important changes occurred in the 
terms of insurance coverage for mental health care. While the vast major- 
ity of plans represent so-called managed indemnity plans (90 percent-94 
percent), the management  of  mental health care benefits changed for a 
substantial number of enrollees between 1991 and 1995. Beginning on  1 
January 1994, about 8 percent of enrollees had their mental health cover- 
age “carved out” to a specialty mental health managed care company.**  In 
January 1995 an additional 35 percent of enrollees had their mental health 
benefits carved out. 
It is reasonable to expect that these carve-out arrangements affected 
both the input prices and the quantities of specific delivered services, such 
as  Changes in the extent of carve-out arrangements might also 
have affected the general clinical strategies used in treating major depres- 
sion. Recent analyses by Wells et al. (1996) and by Berndt, Frank, and Mc- 
Guire (1997) show clear differences  in treatment patterns between carve-out 
managed care plans and treatment of mental health care financed by gen- 
eral health insurers, with carve-out arrangements being associated with a 
higher likelihood of using prescription drug treatments. 
Each outpatient and prescription  drug claim can accommodate two 
ICD-9 diagnostic codes. In identifying cases of major depression, we used 
ICD-9 codes 296.2 (major depressive disorder, single episode) and 296.3 
(major depressive disorder, recurrent episode) to define patients diagnosed 
with major depression.  We  do this for three  reasons. First, the clinical 
trials literature has for the most part employed these definitions in their 
entry criteria. Second, chart reviews have indicated that the specificity of 
these two diagnoses is high (i.e., the proportion of true positives and false 
negatives is high, while the proportion of false positives is very low). Third, 
clinicians could employ a more ambiguous diagnosis such as “depression 
not elsewhere classified” or “neurotic depression.” That clinicians desig- 
nated their diagnosis as either 296.2 or 296.3 indicates a conscious act 
of volition.30 
Using the diagnostic information and dates contained in the claims, we 
construct episodes of treatment. Because we do not directly observe symp- 
toms in retrospective claims data, we  cannot make our claims-based defi- 
nition  of an episode of  treatment correspond directly to an episode of 
28. Specialty carve-out management occurs when a portion of the health risk is managed 
separately from the rest of health care. See Frank, McGuire, and Newhouse (1995) for fur- 
ther discussion. 
29. For discussion, see Goldman, McCulloch, and Sturm (1998), and Ma and McGuire 
(1  998). 
30. Thus we exclude other 296 ICD-9 diagnoses, depression not elsewhere classified, as 
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the illne~s.~'  When claims data indicate that psychotherapeutic drugs were 
prescribed, we consider the number of days of treatment provided by the 
prescription as the time period over which an individual received care. We 
follow American Psychiatric Association (1993) guidelines in defining an 
episode of depression as new if a diagnosis is preceded by a period of at 
least eight weeks of not meeting clinical criteria for depres~ion.?~  Thus 
we  use an eight-week period without treatment to define new  treatment 
episodes. In preliminary analyses, we experimented with alternative defi- 
nitions, such as those involving six- or twelve-week intervals; results were 
essentially unaffected. For treatments lasting longer than six months we 
count quantities of visits and drugs meeting guideline standards for acute 
care occurring with the first six months of care (e.g., fifteen psychotherapy 
visits even if year totals were twenty-five visits). To ensure that we consider 
the full set of claims associated with  the acute phase of treatment, we 
exclude episodes beginning in the last six months of  1995, the last year in 
our sample. 
When these criteria were applied to the MEDSTAT data set, we defined 
18,920 episodes of acute phase outpatient care over the 1991-95  period. 
Because we cannot fully observe the treatment received for censored cases, 
we  confine our attention to the 15,750 uncensored episodes in which we 
observe at least eight weeks without treatment before the beginning of an 
episode; as noted above, 1,548 episodes beginning in the last six months 
of 1995 were also excluded. In order to limit the sample to less severe forms 
of depression, we eliminated individuals with episodes involving inpatient 
hospital treatment for a mental illness any time during the five years. This 
reduced the number of episodes to 10,067. 
Using information on procedures (e.g., type of visit, whether drug pre- 
scribed) as given by the CPT4 codes, we  can describe the composition of 
treatment  that occurred within a treatment  episode. Drug treatment  is 
based on the national drug codes (NDC) reported on the claim. The NDC 
classification of antidepressant medications revealed use of seven TCAs, 
three SSRIs, two other serotonin-related  three MA0 inhibitors, 
four anxiolytics, and four  heterocyclics for treatment  of depression.  In 
terms of composition, 54 percent of  the drug claims involved SSRIs, 19 
percent TCAs, 19 percent anxiolytics, and 7 percent  heterocyclic^.'^ 
In previous research, we  have reported that in the MEDSTAT claims 
31. For discussion of defining episodes of care, see Keeler et al. (1986) and Wingert et 
al. (1995). 
32. We  count days without treatment only after the number of days of supply in a drug 
prescription has been exhausted, thereby assuming full compliance with the daily recom- 
mended dosage. 
33. These were brand name drugs Effexor and Serzone. 
34. These compositional figures are consistent with IMS aggregate national sales data for 
antidepressant medication over this time period, as reported by Berndt, Cockburn, and Gril- 
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database, the share of treatment accounted for by treatment involving psy- 
chotherapy claims appeared to increase significantly in 1995, after having 
fallen steadily from 1991 to 1994.35  Subsequent research has indicated to 
us that while procedure codes are missing for many outpatient claims-a 
common  problem  with claims data, the extent of missing claims in  the 
MEDSTAT data set is particularly large in  1991-94.  Thus, the apparent 
sudden increase in psychotherapy claims in 1995 could simply reflect con- 
siderable missing claims from 1991 through  1994. Hereafter we  call the 
data underlying this previous research our “old” data set. 
To  identify missing psychotherapy claims not explicitly delineated by 
CPT4 codes, for our “new” data set we have developed an algorithm in 
which a psychotherapy procedure code is assigned to claims with missing 
CPT4 codes if  two visits are within fourteen days of each other, if  they 
have the same charge, and if a previously psychotherapy-identified claim 
in the episode has the same charge.36  Use of this algorithm contributed to 
an increase in the number of identified episodes. 
Our primary analysis of the claims data considers only “pure” or “strict 
guideline” treatments. That is, initially we  will only consider episodes of 
care that adhere strictly with treatment definitions as tested in the clinical 
trials literature. In this way we can directly link the “price” of an episode 
of a well-defined treatment to the price of other therapeutically similar 
treatments. However, we will also report results based on findings derived 
from episode treatment definitions that relax this stringent guideline re- 
striction, in which we  include treatments slightly below guideline criteria 
and those involving some continuation phase treatment. 
In our strict guideline analyses we  identify seven major classes of treat- 
ments that have been proven effective in the treatment of depression: (1) 
psychotherapy alone, six to fifteen visits “PT alone”; (2) short-term TCA 
treatment alone or with medical management-“TCA  alone”; (3) short- 
term SSRI treatment alone or with medical management, 31-180  days- 
“SSRI alone”; (4) short-term TCA treatment (3 1-180  days) with  some 
psychotherapy-“TCA+PT”;  (5) short-term  SSRI  treatment  (3  1-1  80 
days) with some psychotherapy-“SSRI  +  PT”; (6) short-term combined 
TCA/SSRI  treatment  (3  1-1 80 days) with  some psychotherapy-“TCA/ 
SSRI +  PT.” With the exception of psychotherapy alone, episodes with an- 
xiolytics also being prescribed are combined into the appropriate class de- 
fined above. Use of seven major classes of treatments in this new data set 
represents an expansion from the five  used in our previously published 
research. Another significant change in the new data was to include epi- 
35. See Frank, Berndt, and Busch (1999) and Frank, Busch, and Berndt (1998). 
36. Additional checks were done to ensure that these newly identified psychotherapy visits 
were not in fact instead a sequence of medical management visits. Robustness checks re- 
vealed that only a small number of claims were reclassified when cost thresholds of  about 
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sodes  that  involved  long-term  treatments  or  those  extending  beyond 
twenty visits or six months. For those episodes we  included the compo- 
nents of care consistent with the acute phase bundles specified above and 
excluded spending on the remainder of the “episode.” Using this expanded 
definition of an episode, we  are more likely to include continuation treat- 
ment in the analysis. This may be especially true in the later years as new 
recommendations  about  continuation  treatment  diffused  into  practice. 
Thus, the new  data set may be “pricing” acute plus early continuation 
phase care in the later years. This would tend to bias an index upward. 
Evidence for this is reflected by an upward trend in the average duration 
of SSRI treatment during the five years (from 87 days in  1991 to 126 in 
1995). This change contributed to a substantial increase in the number of 
cases used in the analyses. 
The new data set also improved the definition of censoring. In the “old” 
data set, to limit our analysis to episodes for which we had information on 
the entire episode, all cases which included treatments in  the last eight 
weeks of 1995 were eliminated. This means that more episodes were elimi- 
nated from 1995 than from any other year. More severe episodes in need 
of  longer  term  treatment  may  therefore  have  been  disproportionately 
dropped from previous analyses. This may have biased  the price index 
downward. We  have now corrected that “late ’95” censoring problem by 
limiting our analysis to the first six months of treatment. As mentioned 
previously, to ensure we  consider all treatments in the first six months of 
the episode, we do not consider episodes begun in the last half of  1995. 
Finally, the new data set allows drug switching if  it is consistent with 
standards of care in clinical trials. Again, the change would tend to in- 
crease the severity and complexity of the treated population. Drug switch- 
ing has been increasing over time as new pharmaceutical agents have be- 
come available (SSRIs and serotonin-norepinephrine reuptake inhibitors 
[SNRIs]). 
It is informative to compare episodes defined in our new data set with 
those in the old. As seen in table 12.1, the most obvious change is that the 
number and proportion of episodes receiving guideline-compatible treat- 
ments increase very substantially, from 2,348 to 5,039, or from 23 percent 
to 50 percent. There are 2,980 guideline-compatible episodes in the new 
data set that were not in the old, and 289 in the old that do not appear in 
the new. 
There is also some evidence suggesting that in the new data set, a greater 
number of episodes are associated with other mental health comorbidities. 
While new-old differences are relatively small in terms of substance abuse 
comorbidities in  guideline-compatible episodes (2.5 versus 2.8 percent), 
17.9 percent of acute phase depression episodes in the new data set simul- 
taneously involve treatment of schizophrenia or bipolar depression, while 
in  the old  data set this proportion was a smaller  15.8 percent. For  the 
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Table 12.1  Comparison of Data Sets Based on New and Old Episode Definitions 
In New but Not  In Old but Not 









Sum of other medical 













2,348  2,980  289 
2.8  2.6  4.2 
15.8  20.1  23.2 
2.9  3.9  6.2 
48.3  47.5  41.5 
36.2  39.3  38.8 
15.6  13.2  19.7 
'Paniclanxiety  diagnoses are ICD-9 300, 300.1-300.4;  schizophrenialbipolar are all 295s, 296.0-296.  I, 
296.4-296.8;  other includes obsessivelcompulsive  disorders (300.3), bulimia (783.6), depression not oth- 
erwise specified (31  I), and dysthymia (300.4). 
medical comorbidities are sense organs, circulatory system, cerebrovascular, digestive system, 
kidneys, prostate, pregnancy, and nervous system. 
versus 2.9 percent. The literature, as well as our own discussions with clini- 
cians, suggests that (1) major depression and bipolar illness are often mis- 
taken for one another, and (2) treatment of depression with comorbid psy- 
choses and substance abuse is both common and difficult. We  interpret 
differences between the new and old data sets as therefore moving us away 
from the more pristine world of clinical trials to a more realistic and more 
complicated treatment environment in which mental illness comorbidities 
are more prevalent. 
It is worth noting that differences between the new and old data sets in 
terms of other, nonmental health comorbidities are rather minor. As seen 
in the bottom panel of table 12.1, for example, the proportion having no 
such comorbidities is 48.2 percent in the new data set, and 48.3 percent in 
the old; relative to the old data set, the proportion having one other medi- 
cal comorbidity is slightly higher (37.9 percent versus 36.2 percent), but is 
slightly lower for two or more comorbidities (13.9 versus 15.6 percent). 
12.5.2  On Guideline Compatibility 
Earlier we  noted that of the 10,067 episodes identified in the new data 
set from 1991 through 1995, 5,039 (50 percent) were guideline compatible. 
It is interesting to note that in our new data set the proportion of episodes 
receiving guideline-compatible treatment rose from 35 percent in 199  1 to 
42 percent in 1992, then increased sharply in 1993 to 56 percent, and re- 
mained at 56 percent in 1994 and 1995. 
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claims data. For example, 1,308 episodes (33 percent of the 3,965) treated 
with psychotherapy alone consisted of a single visit. In addition, 1,672 or 
16 percent  of all episodes received  neither psychotherapy  nor  an anti- 
depressant drug. Such single visits might have taken place for the purpose 
of “ruling out” major depression as the relevant condition to be treated in 
favor of a somatic condition or another mental disorder. In such cases, the 
visit should not be viewed as “inappropriate treatment” but rather as an 
appropriate assessment, consistent with the Depression Guideline Panel 
statement (1993, 36): “Effective treatment rests on accurate diagnosis. The 
practitioner must first determine whether the patient has a clinical depres- 
sion or is simply suffering normal sadness or distress. . . . For patients who 
have very mild cases of major depression or whose diagnosis is unclear and 
who are not in immediate danger or are not suffering significant functional 
impairment, the practitioner may want to schedule one or two additional 
weekly evaluation visits to determine whether symptoms will abate with- 
out formal treatment. . . .” The implication of this is that with retrospective 
claims data, distinguishing treatment and assessment is quite uncertain. 
Hence we  are somewhat unclear as to whether only 50 to 60 percent of 
care lies on the production frontier, or whether another  10 to 20 percent 
of treatments were dealt with properly but did not require treatment of the 
type studied here. It is important to note here that our use of guideline 
standards of care imposes a rather unrealistic shape on the production 
function for treatment of depression. It takes on a step function form. For 
example, if one were to receive six psychotherapy  visits for treatment of 
depression, our analysis would treat the case as “effective,” whereas four 
or five visits would  be viewed as “ineffective.” This is  unlikely to be an 
accurate representation of clinical reality. Nevertheless, there is little sys- 
tematic analysis upon which to make alternative assumptions. Thus, we 
use the step function production model as a point of departure. 
With these difficulties in appropriate interpretation as a caveat, we now 
examine in greater detail the extent of guideline compatibility in the vari- 
ous treatment bundles of the new data set. 
Of the 10,067 episodes, 3,765 were treated with psychotherapy alone, 
and 376 with psychotherapy and anxiolytics. Within the claims data, no 
distinction was made between different types of psychotherapy. Consider- 
ing the 3,044 treatments involving fifty-minute psychotherapy sessions, we 
find that 1,658 received four or fewer visits, and 800 only a single visit. Of 
the 921 episodes involving twenty-minute  psychotherapy alone,  508 in- 
volved just one brief visit, while  178 episodes were treated with between 
two and five brief sessions. An additional twenty episodes involved some 
form of group therapy treatment, with only 25 percent of those having 
more than three visits. 
While clinical trials data indicate that individuals show partial response 
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remission in twelve weeks, published guidelines for the treatment of acute 
phase depression do not indicate any demonstrated effectiveness for fewer 
than six visits. The benefits of short psychotherapy visits, in the absence 
of antidepressant medication, have not been studied and therefore cannot 
be considered either effective or ineffective treatment. Although clinical 
trials and published treatment guidelines indicate psychotherapeutic treat- 
ment alone is  an effective treatment, in our data, of  the 3,044 episodes 
given this treatment, only 1,386 episodes (46 percent) can be considered 
to have completed a psychotherapy regimen that is consistent with guide- 
line  treatment^.^' 
Turning attention now to treatments involving antidepressant medica- 
tions, we begin by noting that claims data do not include information on 
how many days medication was actually taken; as a proxy,  we  use the 
number of days of treatment for which a prescription was filled. 
Of  the 10,067 episodes considered, 231 were treated with TCA either 
alone (176) or in combination with anxiolytic medication (55). Of these 
231 episodes, 55 (24 percent) were treated with fewer than thirty days of 
medication and 29 were treated with ten or fewer days. Generally, the clini- 
cal literature (and the APA guidelines) indicates that while patients may 
show some improvement from antidepressant medication by  the end of 
the first week, full response to acute phase depression may  take four to 
six weeks. 
An additional 741 episodes were treated with SSRIs either alone (604) 
or in  combination with  anxiolytic medication (137); 77  (10 percent)  of 
these episodes were treated with fewer than thirty days of medication. Be- 
cause individuals have differing reactions to drugs, some individuals are 
appropriately treated with one class of antidepressants, and then switched 
to another class. In our sample, 95 episodes were treated with both TCAs 
and SSRIs, but 20 of these episodes had less than thirty days of both drugs. 
Several episodes were treated with medications other than SSRIs and 
TCAs. In our sample 10 episodes were treated with MA0 inhibitors, while 
164 were  treated  with  heterocyclics. An  additional  124  episodes were 
treated with antianxiety medication alone, a protocol which has not been 
approved by  the FDA for the treatment of major depression. The use of 
antianxiety medication in the treatment of depression remains controver- 
sial. The use of alprazolam may  be  appropriate, if  other  medication is 
contraindicated. There is no clinical trial evidence for the efficacious use 
of other anxiolytic  medication^.^^ 
Finally,  in  terms  of  combination  treatments,  the  share  of  episodes 
treated with psychotherapy and antidepressant medication grew over time. 
Over  the entire five-year period,  552  treatment  episodes involved  both 
37. For a related discussion, see Katon et al. (1992). 
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some TCA and some psychotherapy, while 2,169 included both SSRI and 
some psychotherapy. A large share (36 percent) of the episodes treated 
with combination treatments had three or fewer psychotherapy visits, and 
an additional 382 episodes were treated with some TCA, some SSRI, and 
some psychotherapy. 
12.5.3 
The patterns  of care observed  in this data set raise issues related to 
the likely effectiveness of treatment, given the substantial proportion of 
episodes involving guideline-incompatible treatments. One potential criti- 
cism of the patterns of treatment bundle data presented above is that they 
are based on retrospective claims data. Claims data are useful in that the 
retrospective  medical  treatment  of  many  individuals  can  be  analyzed 
efficiently and at minimal expense. In addition, such observational data 
reveal the “real world” practice of medicine, not the pristine clinical trial 
environment. Claims data are also used for quality assessment by  organ- 
izations  constructing  “report cards”  on  health  care  organizations.  Yet 
claims data have been fairly criticized for several reasons. The accuracy of 
diagnoses and recorded data are sometimes questioned, and omissions in 
records are common. For example, depression has been shown to be un- 
derdiagnosed by primary care physicians and overdiagnosed by psychiat- 
ric clinicians (Schulberg et al. 1985). 
Other studies have found treatment patterns for depression that are gen- 
erally consistent  with the patterns we  observe here. The Medical  Out- 
comes Study (MOS) consisted of 635 individuals diagnosed with depres- 
sion or with current depressive symptoms for whom data were collected 
by  self-administered questionnaires, patient diaries, phone interviews, and 
health examinations. The MOS found that only 23 percent of depressed pa- 
tients had used an antidepressant medication in the prior month or used it 
daily for a month or more in the prior six months. Of those patients using 
an antidepressant medication, 39 percent used an inappropriately low dose 
(Wells et al. 1994). 
The MOS did not report number of psychotherapy visits. Instead it re- 
ported  “counseling,” defining it as’ three or more minutes of counseling 
during the screening interview. This makes comparison with  published 
standards of  care difficult. Although  90 percent  of  patients  of  mental 
health  specialists  were counseled,  among general  medical  practitioners 
where most study participants were treated, only 20 percent of managed 
care and 40 percent of fee-for-service patients were counseled. 
Another study of eighty-eight outpatients enrolled in the Clinical Re- 
search Collaborative Program on the Psychobiology of Depression of the 
National  Institute of Mental Health (NIMH) found that prior to entry 
into the study, only 19 percent of patients received an adequate dose and 
duration  of  antidepressant medication, while 24  percent received some 
Comparison with Results from Other Studies Treatment Price Indexes for Acute Phase Major Depression  485 
antianxiety medication. Regarding psychotherapy visits, 44 percent were 
seen for at least one hour weekly (Keller, Lavori, Klerman et al. 1986). 
Thus, the substantial proportion of patients in the MOS and NIMH 
studies apparently not obtaining efficacious treatments, while perhaps sur- 
prising, is consistent with the treatment patterns found in the claims data 
we  observe here. 
For  our purposes  of constructing price  indexes for the  treatment  of 
acute phase major depression, we must decide whether to utilize the data 
suggestive of treatment not consistent with Food and Drug Administra- 
tion (FDA) approvals and Agency for Health Care Policy and Research 
(AHCPR) guidelines. Since the interpretation of such treatments is prob- 
lematic, in our “strict guideline” analysis we  confine our attention to epi- 
sodes of treatment defined as being consistent with AHCPR guidelines; 
however, in a separate analysis we also include treatment bundles that are 
“close”  to  guideline  standards.  Additional  research  on  guideline- 
incompatible care and the shape of the production function for treatment 
of depression is currently under way. 
12.6  Quantities and Prices of Alternative Treatment Bundles 
We begin our empirical analysis by characterizing quantities and prices 
of  the  seven  treatment  bundles.  In  table  12.2  we  report  guideline- 
compatible treatment quantities by  year. Censoring at the beginning and 
end of our time span implies that in 1991 and in 1995, about 1,500  episodes 
are identified, whereas in  1992-94  the number is considerably larger at 
about  2,400  per  year.  The  two  most  common  treatment  bundles  are 
SSRI+PT and PT alone. Because of varying sample size by year, quantity 
trends are more easily discerned by examining quantity proportions rather 
than absolute levels; guideline-compatible treatment bundle quantity pro- 
portions are reported in table 12.3. 
A number of notable trends appear in table 12.3. First, there has been 
Table 12.2  Guideline-Compatible  Treatment Bundle Quantities, by Year 
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Table 12.3  Guideline-Compatible Treatment Bundle Quantity Proportions, by Year 
Treatment  1991  1992  1993  1994  1995  Total 
PT alone  0.409  0.331  0.237  0.224  0.275  0.275 
TCA alone  0.061  0.048  0.032  0.027  0.023  0.035 
SSRI alone  0.100  0.120  0.139  0.147  0.132  0.133 
TCA +  PT  0.121  0.118  0.095  0.052  0.040  0.081 
SSRI+PT  0.239  0.31  1  0.390  0.463  0.480  0.395 
TCAISSRI  0.017  0.01  5  0.017  0.017  0.001  0.015 
TCNSSRI  +  PT  0.052  0.056  0.089  0.070  0.044  0.067 
a very substantial decline in PT alone treatments, from 4  1 percent in 199  1 
to 22 percent in 1994, and then up slightly to nearly 28 percent in 1995. 
Second, for the medication only treatments, SSRI alone has grown from 
10 to 13 percent, even as TCA alone declined from 6 to 2 percent; the sum 
of the two medication only treatments has remained relatively constant at 
15 to 16 percent. Third, most of the compositional change among treat- 
ment  bundles  has  involved  the  medication-psychotherapy  combination 
treatments. While the TCA+PT combination fell from 12 to 4 percent be- 
tween 1991 and 1995, the SSRI+PT treatment share doubled, from 24 to 
48 percent of all treatments. By 1995, the SSRI+PT combination had be- 
come the modal treatment bundle. 
In table 12.4 we report the average supply price for each treatment bun- 
dle, by  year; recall that this supply price captures the sum of payments 
from insurers and patients/consumers to providers. As is seen there, annual 
price movements represent a mix of increases and decreases. Between 1993 
and 1994, for example, the price of one bundle increases and that of all 
other six bundles decreases, while for 1994-95.  price movements are re- 
versed-six  up, and one down. Of particular interest is the extent to which 
compositional changes in  quantities of  treatment bundles  appear to be 
negatively related to changes in relative prices. When entries in tables 12.3 
and  12.4 are considered  together,  it  becomes  clear  that  compositional 
quantity changes do not follow simple conceptions of downward-sloping 
demand curves where quantity and “price” changes are clearly negatively 
related. From 1991 to 1992, for example, even as the supply price of SSRI 
alone more than doubled from $52 to $1 13, the SSRI alone share increased 
from 4 to 6 percent; similarly, the cost of the SSRI+PT combination bun- 
dle increased by  about 150 percent from $125 to $292 between 1991 and 
1992, yet the quantity share grew from 24 percent to 31 percent. It is im- 
portant to note that the quality of treatment bundles may vary (e.g., side 
effects). Also, insurance coverage drives a wedge between the supply and 
demand prices. Both of these factors may help explain observed patterns 
and they are discussed below. 
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share is observed in other years as well. From 1992 to 1993, for example, 
the supply price of TCA+PT fell by  about 18 percent from $882 to $745, 
but its quantity share also dropped from 12 percent to 10 percent. Between 
1993 and 1994, while the cost of PT alone fell about 5 percent from $866 
to $8 18, the PT quantity share fell from 26 percent to 23 percent. Similarly, 
for both TCA alone and TCA+PT, between  1993 and 1994 both prices 
and quantity shares fell. 
What these quantity  and supply price data suggest, therefore, is  that 
factors other than supply price are likely to have induced compositional 
changes  among  treatment  bundles  for  acute  phase  major  depression. 
Prominent among these, we  conjecture, is the increased knowledge and 
experience gained by  physicians on the efficacy and effectiveness of  the 
SSRI medications, particularly in combination with a limited amount of 
psychotherapy and changing insurance arrangements. 
Although compositional changes among treatment bundles may reflect 
a host of price and nonprice influences, it is clear that the dollar expendi- 
ture shares among the seven treatment bundles have been greatly affected 
between 1991 and 1995. These dramatic changes are evident in table 12.5. 
While the expenditure share going to PT alone fell from 45  percent  to 
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Table 12.5  Total Expenditure Shares by Treatment Bundle, by Year 
Treatment  1991  1992  1993  1994  1995  Average 
PT alone  0.446  0.346  0.256  0.232  0.273  0.310 
TCA alone  0.018  0.018  0.013  0.007  0.006”  0.012 
SSRI alone  0.038  0.057  0.054  0.058  0.055  0.052 
TCA +  PT  0.140  0.128  0.089  0.047  0.045  0.090 
SSRI+PT  0.280  0.374  0.461  0.563  0.565  0.449 
TCA/SSRI  0.014‘  O.OO?  0.010  0.009  0.003”  0.008 
TCAISSRI  +  PT  0.064  0.071  0.118  0.085  0.053  0.078 
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27 percent between 1991 and 1995, by  1995 the SSRI+PT bundle was re- 
sponsible for more than half (56 percent) of all dollar expenditures, up from 
28 percent in 199  1. In 199  1  the three single bundles of PT alone, TCA alone, 
and SSRI alone accounted for 50 percent of all treatment dollars in 1991, 
but by  1995 they only captured 33 percent of expenditures. 
Together, the patterns observed in tables 12.2 through  12.5 suggest to 
us that rather than PT and the SSRIs being viewed as simple single substi- 
tutes in the production of treatments for acute phase depression, they are 
more accurately envisaged as being complementary in the sense that the 
PT+ SSRI combination has now become the modal treatment. 
To this point, our discussion of treatment bundle price has focused on 
the supply price-the  sum of  payments received from insurers and pa- 
tientskonsumers. The demand price notion reflects the fact that patients 
receiving treatment for acute phase depression provide direct payments in 
the form of copayments and deductibles. In table 12.6 we  report average 
demand prices for each of the seven treatment bundles, annually. Trends 
in the demand price differ quite markedly from those of the supply price. 
Recall from table 12.4 that the average supply price across all bundles 
fell slightly from $805 in 1991 to $788 in 1994, and then increased to $825 
in 1995. In contrast, as seen in table 12.6, from 1991 to 1994 the average de- 
mand price increased from $100 to $105, and then it increased very sharply 
to $128 in 1995. This sharp increase of 22 percent between 1994 and 1995 
in the average demand price across all treatment bundles reflects corre- 
sponding jumps in the PT alone (26 percent),  SSRI alone (19 percent), 
SSRI +PT (17 percent), and TCA/SSRI+PT (21 percent) bundles. 
Two main factors may account for changes in demand prices that differ 
so starkly from supply price changes. First are the changes in cost-sharing 
provisions. These are documented in the MEDSTAT data set. The MED- 
STAT data indicated to us that in 1995, for a number of insurance plans, 
benefit changes were introduced  that  substantially  increased the copay- 
ments and deductibles required of plan  enrollee^.^^ Second is the tendency 
to use out-of-network providers in the context of managed care. Coverage 
of care provided by nonnetwork providers typically carries higher copay- 
ments than does care received from a network clinician. During the time 
period observed, networks were becoming more restrictive and behavioral 
health carve-outs were introduced, which may have increased the share of 
care provided by nonnetwork providers. The impact of these benefit design 
changes can be seen by computing the portion of the total treatment cost 
39. Data from Marion Merrell Dow’s Managed  Care Digest  (1993-1994,  1996) indicate 
that over all HMOs surveyed, average copayment per prescription rose from $6.78 in  1993 
to $7.43 in  1995 for brand name drugs, and from $4.75 to $5.22  for generics. While the 
MEDSTAT increases appear to be  larger, they also include deductibles for psychotherapy 
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Table 12.6  Average Demand Price of Treatment Bundle, in Dollars, by  Year 
Treatment  1991  1992 
PT alone  121  122 
TCA alone  39  46 
SSRI alone  23  30 
TCA +  PT  128  124 
SSRI+PT  102  105 
TCA/SSRI  43”  47” 
TCA/SSRI+PT  102  121 
Averaged  100  101 
1993  1994  1995 
122  123  155 
46  48  51 
24  27  32 
116  113  117 
115  121  142 
131  135  163 
102  105  128 









~~  ~ 
”Denotes  a weighted average. 
bDenotes a cell with less than twenty observations. 
borne directly by  the patient, that is, computing the ratio of the demand 
price in table 12.6 to the corresponding supply price in table 12.4; we  call 
this the OOPPs ratio. 
For the SSRI alone bundle, the OOPPs ratio increased only marginally, 
from 7 percent in 1991 to 9 percent in  1995. For the very low total cost 
TCA alone bundle, the OOPPs ratio increased more markedly, from 16 
percent in 1991 to 23 percent in  1995; in absolute terms, this additional 
burden borne by the patient was only $12 (from $39 to $51). For the com- 
bination treatments involving PT and the SSRIs, however, the increase was 
much more substantial, both in terms of OOPPs ratio and absolute dollar 
burden. In the SSRI-tPT bundle, for example, the OOPPs ratio rose from 
11 percent to 15 percent between 1991 and 1995, with the demand price 
increasing $40 from $102 to $142; even more dramatically, for the TCA/ 
SSRI+PT bundle the OOPPs ratio rose from  10 percent to  17 percent, 
while the demand price jumped $61 from $102 in 1991 to $163 in  1995. 
The changes resulted from increased cost sharing for psychotherapy. 
One important implication of  these findings is  that when considering 
construction of price indexes for the treatment of a medical condition such 
as depression, it is imperative that demand prices be distinguished from 
supply prices, for changes in insurance plan design benefits over time can 
introduce sharp differences into their time trends. 
12.7  Aggregate Price Indexes for the Treatment of  Depression 
With the prices and quantities of the seven treatment bundles as elemen- 
tary building blocks, we  now  move on to the construction of aggregate 
supply and aggregate demand price indexes. A variety of price indexes can 
be computed, each having implicit assumptions on the extent of ex  ante 
substitutability among the seven bundles. Since we  have discussed these 490  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
alternative  index  number  formulas  and  underlying  assumptions  else- 
where,40  and since they are well known in the literature on index  number^,^' 
we provide only a very brief discussion here. 
Fixed quantity weight indexes such as Laspeyres and the Paasche in- 
dexes reflect an assumption  of zero  ex  ante substitutability among the 
seven  treatment  bundles;  the  Laspeyres  employs  a  base-period  fixed 
weight, the Paasche the final-period fixed weight. The Cobb-Douglas em- 
ploys  a fixed expenditure weight (here, equal to the mean  expenditure 
share for each bundle over time), and assumes that the elasticity of substi- 
tution  among treatment  bundles equals  unity  for  all pairs  of  bundles. 
When demand curves are downward sloping and bundle prices are all in- 
creasing, between any two adjacent time periods the Laspeyres price index 
is greater than the Paasche. 
In general the chained, or sequentially updated, price indexes are viewed 
as being preferable to the fixed-weight indexes. The Tornqvist discrete ap- 
proximation to the Divisia, and the Fisher ideal, make no a priori assump- 
tions on the extent of substitutability among treatment bundles. The Torn- 
qvist weights percentage changes in each of the treatment bundles by the 
arithmetic mean of the expenditure share in the two time periods, whereas 
the Fisher ideal is  the geometric mean of the corresponding  Laspeyres 
and Paasche indexes. A commonly observed empirical pattern is that the 
Tornqvist and Fisher ideal price indexes are very close to one another, and 
both tend to be in between the Laspeyres and Paasche price indexes. 
With  this as background, we  now report results of various aggregate 
price index calculations, first in table 12.7 as viewed from the supply price 
(i.e., PPI) vantage, and then in table 12.8 from the demand side (i.e., CPI). 
The most  striking result  that immediately emerges from table  12.7 is 
that, regardless of which index number procedure is employed, over the 
1991-95 period the treatment price index for acute phase major depression 
has hardly changed, remaining at 1.00 or falling slightly to around 0.97. 
Each of the price indexes reveals an increase from 1991 to 1992, they all 
fall in 1993, all fall again in  1994 (to between 0.95 and 0.97), and then all 
increase in 1995. Given some of the data problems in 1995, this last finding 
should be viewed with caution. Differences among the various fixed and 
chained indexes are relatively minor. 
By comparison, in the bottom panel of table 12.7 we report various PPIs 
published  by  the BLS. Over the  1991-95  period, the aggregate PPI for 
all finished goods increased about 5 percent, and that for antidepressant 
prescription drugs increased by about 20 percent. From 1992 to 1995, the 
PPI for psychiatric hospital services increased by about 10 percent, while 
between 1994 and 1995 the overall health services PPI increased 2.4 per- 
40. See Frank, Berndt, and Busch (1999) and Frank, Busch, and Berndt (1998) 
41. See, for example, Diewert (1976, 1981). Treatment Price Indexes for Acute Phase Major Depression  491 
Table 12.7  Alternative Aggregate Producer (“Supply”) Price Indexes for the 
Treatment of Acute Phase Major Depression 






























































dBLS  indexes are normalized to appropriate base year. 
Table 12.8  Alternative Aggregate Consumer (“Demand”) Price Indexes for the 
Treatment of Acute Phase Major Depression 














1.000  1.028 
1  .ooo  1.037 
1.000  1.037 
1.041  1.063 
1.080  1.118 




1.000  1.028 
1.000  1.032 
1  .ooo  1.030 
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1.048  1.081 
1.065  1.104 
1.056  1.092 





1 .ooo  1.030 
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1.000  1.075 
1.061  1.088 
1.146  1.205 




*BLS  indexes are normalized to 1991 base year. 
cent. Thus, while our various supply price indexes for the treatment  of 
acute phase depression are either flat or very slightly falling, they all grow 
considerably less than the various official PPIs. The “real,” all-items CPI 
inflation-adjusted price index for the treatment of acute phase depression 
has fallen over the 1991-95  time span. 
Index number afficionados might notice, however, that the typically ob- 
served inequality  relationships among the Laspeyres and Paasche price 
indexes are not present here. For example, for both fixed- and chained- 492  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
weight versions, the Paasche price index is larger than the Laspeyres. The 
reason this occurs is that, as noted in section 12.6 above, in a number of 
cases changes in treatment bundle supply prices and quantity shares are 
positively rather than negatively correlated. Because the price index calcu- 
lations do not take into account factors affecting demand other than price, 
and because consumers do not face supply prices, there is the appearance 
of a positive relation between quantity and supply price. We discuss other 
price-related issues in section 12.8 below, where we  deal with hedonic price 
indexes. Finally, note that  as is  usually the case, the Fisher  ideal  and 
Tornqvist indexes are always in  between the chained Paasche  and Las- 
peyres indexes. 
We now turn to a discussion of aggregate price indexes viewed from the 
demand side, or the patients’ consumers’ OOPPs. As seen in table  12.8, 
the demand aggregate price indexes have very different time trends than 
do the supply aggregate price indexes. Each of the price indexes exhibits 
an increase between each pair of  adjacent years, with the 1994-95  price 
increase being particularly  dramatic. By  1995, the fixed-weight price in- 
dexes (normalized to 1.000 in  1991) ranged between  1.27 and 1.33, while 
the chained indexes had a slightly smaller variation, between 1.28 and 1.32. 
Between 1991 and 1994, the price indexes increased by only about 10 per- 
cent, but in 1995 the increase was much larger, averaging around 20 per- 
cent. As discussed in section 12.6, we  attribute this sharp increase to ben- 
efit  design  changes  in  1995  that  increased  patient  copayments  and 
deductibles. 
The discrepancy between the PPI and CPI results highlights several im- 
portant points in interpretation of the data. First is that if  the elasticity 
with respect to the demand price is less than unity (in absolute value), 
spending must increase. Because cost sharing increased notably and de- 
mand estimates suggest an elasticity of less than unity, it is not surprising 
that the CPI increases over time. Second, and more important, is the wel- 
fare interpretation of  these changes. It is well  known that  low  levels of 
demand side cost sharing in medical insurance are associated with welfare 
losses due to moral hazard (Newhouse et a]. 1993). Thus, changes in the 
CPI for depression may reflect reduced moral hazard in addition to higher 
prices per  unit  of  “effective care.” Research by  Manning  and Marquis 
(1989) suggests that 50 percent cost sharing for mental health care was 
optimal in a fee-for-service context. Because observed rates in our data 
are quite a bit lower, gains from reduced moral hazard may be signifi- 
cant. Since interpretation of the CPI is unclear, we focus more attention on 
the PPI. 
12.8  Hedonic Price Indexes 
An enduring issue in price index measurement is how one should make 
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here, for it is reasonable to expect that the characteristics and attributes of 
the acute phase of treatment for depression have changed over time, and 
that  changes in the  underlying patient  population  might also have  oc- 
curred. 
Although its use to date in the medical marketplace has been limited, 
the hedonic price approach has been used in many other contexts to adjust 
price movements for (not fully priced) quality changes.42  We  now briefly 
outline our implementation of hedonic price measurement for the treat- 
ment of acute phase depression. 
We  expect that  treatment costs for depression are affected by  patient 
characteristics, various attributes of antidepressant medications, the type 
of treatment given the patient, and the year in which the treatment episode 
began. Patient characteristics for which we have data include the patient’s 
gender, age, general medical condition (measured by the number of comor- 
bid general medical conditions, as noted on the bottom of table 12.  l), the 
industry in which the plan enrollee is employed (transportation, communi- 
cation, and utilities; services; or government), and information on the pa- 
tient’s mental health comorbidities. With respect to these mental health 
comorbidities, we  construct dummy variables for whether the patient is 
also diagnosed with a substance abuse disorder, a paniclanxiety disorder, 
schizophrenia or bipolar depression, depression not otherwise specified, 
and whether the current episode involves a recurrence of major depression. 
For attributes of the various antidepressant medications, we  employ data 
on the half-life of the medication and on the number of side effects that 
frequently accompany use of the medi~ation.~~  Regarding treatments, we 
create dummy variables for each of  the seven guideline-compatible treat- 
ment bundles described earlier. We  also create a dummy variable indicat- 
ing whether at the start of  the episode the individual was enrolled in a 
behavioral health carve-out. Finally, we create dummy variables indicating 
the year in which the treatment episode began. 
The dependent variables in the hedonic regressions are the natural loga- 
rithm of the supply price and of the demand price. The explanatory vari- 
ables are the patient, medication, treatment, and time variables discussed 
above. The set of omitted dummy variables, and thus the reference case, 
is that for a female; where the enrollee is employed in the transportation, 
communication, or utilities industries; has none of  the mental health co- 
morbidities noted above; is not being treated for a recurrent episode of 
acute phase depression; treatment consists of PT alone; and the treatment 
episode began in 1991. Parameter estimates for the supply price equation 
42. For an introductory discussion to the hedonic method, see Griliches [1988), chapters 
7 and 8, and Berndt [1991), chapter 4. Applications in the medical context include Trajten- 
berg (1990) and Berndt, Cockburn, and Griliches (1996). 
43. The side effect data are discussed in detail in Berndt, Cockburn, and Griliches (1996). 
We  sum up the 0 (rare) to 4 [common) ratings across the various side effects. Here we  also 
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are in the left-hand panel of table 12.9, while estimates for demand price 
equation are in the right-hand panel. A number of results are worth men- 
tioning in detail. We begin with the supply price. 
First, characteristics of the patient and his or her illness have a statisti- 
cally significant impact on treatment costs. While age does not appear to 
affect the supply price, mental health comorbidities such as anxiety/panic, 
schizophrenia/bipolar depression, and depression not otherwise specified 
all have a positive and significant impact. Somewhat surprisingly, comor- 
bid substance abuse has a negative coefficient estimate, although not sig- 
nificant. The sum of the patient’s other general medical comorbidities is 
also negative, but not significant. Finally, treatment costs for patients in 
which the enrollee is employed in the services or government sectors are 
considerably lower than if the industry involves transportation, communi- 
cations, or utilities. 
Second, attributes of the antidepressant medications also affect supply 
prices of treatment, even when one controls for type of treatment. Specifi- 
cally, within the various bundles involving prescription drugs, greater side 
effects are associated  with  lower  supply prices  (lower side effects with 
higher supply prices), and increased half-life of the drug (mitigating the 
negative impacts of occasionally forgetting to take the medication) also 
raises the supply price. Relative to PT alone, treatment with TCA alone 
or SSRI alone reduces the supply price significantly, while use of  SSRI + 
PT or TCA/SSRI + PT increases supply price. 
Somewhat surprisingly, we  find that whether  at the beginning of  the 
treatment episode the patient was enrolled in a mental health carve-out 
has no significant impact on supply price. To check whether the carve-out 
impact was diluted because of differential treatment bundles used by the 
carve-out, we also estimated a supply price equation in which the treat- 
ment bundle dummy variables were deleted; results are given in the second 
column of parameter estimates in table 12.9. Although the goodness of fit 
was reduced considerably when the treatment bundle variables were de- 
leted, the carve-out parameter estimate remained insignificant. This may 
be due in part to the fact that the comparison conditions involved managed 
indemnity arrangements which tend to negotiate price discounts and shift 
care patterns. 
Of particular interest are the parameter estimates on the 1992-95  yearly 
dummy variables. In the context of the hedonic price equation, these pa- 
rameter estimates indicate how the supply price changed relative to 1991, 
holding constant the various patient characteristics, medication attributes, 
and the treatment bundle composition. Each of the four parameter esti- 
mates is small and insignificantly different from zero; hedonic price in- 
dexes computed as antilogarithms of  these coefficients are  1.049, 1.004, 
0.980, and 1.027 for 1992 through 1995, respectively (1991 = 1  .OOO).  These 
quality-adjusted  hedonic price indexes are consistent with traditional ag- 
gregate supply price indexes reported in table  12.7 above. Adjusting for Table 12.9  Parameter Estimates from Hedonic Price Regressions 
Supply Price (“PPI”)  Demand Price (“CPI”) 
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various patient, medication, and treatment changes over time does not 
appear to affect the central finding that from 1991 to 1995 there was very 
little change in the supply price for treating acute phase major depression. 
We now turn to the demand price hedonic equations, whose parameter 
estimates appear in  the last two columns of table  12.9. In general, the 
pattern of results from the hedonic demand price equations involving qual- 
ity attributes is not as strong and dramatic as is that of the hedonic supply 
price equation. For example, while parameter estimates on the patient’s 
mental health comorbidities are of the same sign, in the demand price 
equation several of them are no longer statistically significant; attributes 
of the antidepressant medication are not significant as well. As with the 
supply equation, the mental health carve-out coefficient is insignificant. 
However, in contrast to the supply price equation, for the demand he- 
donic price equation the parameter estimates on the 1992-95  year dummy 
variables are positive, and by  1994 and 1995 they become statistically sig- 
nificant. Relative to 1991 = 1  .OOO, holding constant patient characteristics, 
medication attributes, and treatment composition, the hedonic price in- 
dexes for 1992-95  (computed as antilogs of  the estimated parameters) are 
1.114, 1.121, 1.155, and 1.443. Compared to the traditional aggregate de- 
mand price indexes reported in table 12.8, the time trends in these hedonic 
price indexes are broadly similar. While the traditional aggregate demand 
price index in table  12.8 averages about 1.30 in  1995, the corresponding 
hedonic quality-adjusted demand price index is 1.44; if one takes the anti- 
log of the 1995 parameter estimate in table 12.9 minus one times the robust 
standard error, one obtains a 1995 price index of about 1.34, not much dif- 
ferent from that in table 12.8. We conclude, therefore, that traditional and 
hedonic approaches to price index measurement yield broadly similar re- 
sults. 
12.9  Discussion 
Our goal in this research project has been to extend previous research 
aimed at constructing CPI- and PPI-like medical price indexes that deal 
with prices of treatment episodes rather than prices of discrete inputs, that 
are based on transaction rather than list prices, that take quality changes 
and expected outcomes into account, and that employ more current expen- 
diture weights in the aggregation computations. Although we  have made 
considerable progress in achieving this goal, we believe a number of cave- 
ats are in order. 
First, the results reported here differ considerably from those reported 
earlier in Frank, Busch, and Berndt (1998) and Frank, Berndt, and Busch 
(1  999); there we  reported substantial supply and demand price declines 
over the 1991-95  period. Although we  are still examining why the differ- 
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data set we bring in many more patients. The evidence suggests that over 
time the new data set has an increasing share of patients with (1) more 
complicated conditions, (2) greater severity of illness, and (3) elements of 
longer term treatments such as continuation phase care. While the older 
data set may have corresponded with episodes more closely approximating 
the pristine world of clinical trials, the larger, new data set involves patients 
with more typical complicated illnesses. 
It is therefore of interest to examine how robust are our new data set 
findings when one relaxes the strict guideline-compatible standards we im- 
posed in defining episodes of care. We have created yet another data set, 
where we relaxed the definitions of the seven bundles. Bundles which con- 
sider drugs alone as treatment remain unchanged at 30 to 180 days of 
treatment. Definitions of bundles which include psychotherapy have been 
expanded such that the cost of up to twenty psychotherapy visits is now 
included in the cost of the episode. Furthermore, for the treatment “psy- 
chotherapy alone” we previously allowed for a minimum of five visits. This 
constraint was relaxed to include episodes treated with three or four visits. 
Appendix table 12A.  1 shows that with the broader definition of standards 
of care the price indexes are largely unchanged. Specifically, they are rather 
flat, not falling below 2 percentage points in comparing 1991 and 1995. 
It is also useful to comment on implications of our research findings. 
Using alternative index number procedures, we find that over the 1991-95 
time period, the nominal supply price of acute phase treatment for depres- 
sion is essentially unchanged, while the real supply price (relative to GDP 
deflator) has declined. Note that this may well create an upward bias in 
estimated price movements for acute phase treatment of depression. Recall 
that we  showed that the percentage of episodes meeting guideline stan- 
dards has increased over time. The price indexes reported above do not 
account for this apparent move toward the production frontier. Improved 
compliance with standards of care implies greater benefits are being gener- 
ated over time, thereby understating price reductions of effective care. The 
demand price index revealed a steady 2 to 3 percent per year increase from 
1991 to  1994, which is then followed by  a sharp 20 percent increase in 
1995. Since the demand price encompasses only consumers’/patients’ di- 
rect OOPPs, and since the supply price is the sum of consumer plus insurer 
payments, it follows that from 1991 to 1994 there was steady 2 to 3 percent 
annual decrease  in insurers’ expenditures, and that in 1995 a very substan- 
tial  20 percent  decrease took place. While the nominal  supply price  of 
acute phase treatment for depression was apparently unchanged between 
1991 and 1995, the compositional burden shifted from third-party insurer 
to patient. The change in incidence of payment, in large part due to in- 
creased patient copayments and deductibles, likely reflects efforts by insur- 
ers to deal with moral hazard via design of mental  health benefits and 
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Our research findings based on index number procedures are broadly 
consistent with those based on simple hedonic price methods, particularly 
with the supply price. On the demand side, the hedonic price index in- 
creases more rapidly up to 1994, and then increases more sharply in  1995 
than do the traditional  index numbers.  Note that  what we  call “tradi- 
tional” here, however, represents a substantial departure from current BLS 
practice, in that we  have used as elementary building blocks the transac- 
tion prices accompanying alternative treatment bundles, and not the (list) 
prices of  fixed  set of  inputs.  Nevertheless,  it is  interesting that,  as  in 
Berndt, Cockburn, and Griliches (1996), the marginal impact of incorpo- 
rating hedonic pricing methods is  not that significant, once one defines 
output quantities carefully. Our hedonic research could have gone several 
steps further, allowing for changing parameters over time and integrating 
the estimated hedonic price equations with index number procedures, but 
we  leave those nuances for further research.44 
Finally, it is worth commenting on implications of this research for pro- 
cedural revisions currently under consideration at the BLS. The BLS is 
responsible for constructing and publishing PPIs and CPIs for a very large 
number of  medical-related services and commodities. Our research has 
focused on but one disorder-major  depression-albeit  one whose output 
measurement presented considerable challenges. We  believe that econo- 
mies of scope and scale are undoubtedly available, and we  have experi- 
enced a steep learning curve in working with the MEDSTAT data. We also 
believe that extension of the treatment episode approach to other illnesses 
and disorders is feasible. Nevertheless, we are struck by how difficult, time- 
consuming, and expensive this research has been for us.  If  a treatment 
episode approach is to be implemented efficiently at the BLS (or elsewhere, 
such as at HCFA), considerable care needs to be exercised in choosing a 
set of illnesseddisorders for which treatment bundles can be well defined, 
for which quality comparisons can readily be made (facilitated by AHCPR 
or other published professional guideline standards), and for which claims 
data can readily be employed. 
12.10  Concluding Remarks 
We  have implemented an approach that employs transaction data from 
a publicly available retrospective medical claims database of almost half a 
million lives, annually from 1991 to 1995. Based on a review of the clinical 
research literature dealing with the acute phase of treatment for depres- 
sion, we  identify seven alternative service bundles that combine varying 
types and quantities of prescription drugs, medical management, and psy- 
chotherapy. We  construct data on episodes of  treatment and their cost. 
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Because the treatment bundles are viewed by the medical community as 
being therapeutically similar in terms of ex ante efficacy, our linking of 
treatment bundles provides an important step toward incorporation of ex- 
pected medical outcomes. We distinguish a supply price index, similar to 
the BLS PPI, that represents the total receipts received by  providers of 
medical treatment (from the insurer and the patient), from a demand price 
index (similar to the CPI) that incorporates only the out-of-pocket pay- 
ments (via copayments and deductibles) by the patientkonsumer. Finally, 
we employ a variety of traditional aggregate index number formulas, con- 
sistent with varying assumptions concerning the ex  ante substitutability 
among the seven treatment bundles, as well as hedonic price procedures 
in computing price indexes. 
For the supply side price index, the various price indexes all point to a 
flat and essentially unchanging price over the 1991-95  period. Because the 
BLS’s various producer  price indexes all indicate  a significant increase 
over the same time period, our results suggest that in real terms, the supply 
price for treatment of acute phase depression has fallen over time. On the 
demand side, however, the indexes show a total increase in price of about 
10 percent between 1991 and 1994, and then a very sharp 20 percent in- 
crease. The usual welfare interpretation of the CPI is not possible in this 
case. The price  increase largely reflects increased cost sharing arrange- 
ments which are certain to reduce welfare losses stemming from moral 
hazard. This is especially the case in MEDSTAT data, which generally 
cover plans with substantially lower cost sharing for mental health care 
than is typical in the economy as a whole (20 percent versus 50 percent). 
Our research can be extended in a number of ways. Two issues are par- 
ticularly important. First, although we have experimented with use of both 
strict and somewhat relaxed guideline criteria to define episodes of care, 
in each case we have assumed an “all or nothing” treatment. The implicit 
production function therefore involves a steep step or cliff in which treat- 
ment either is or is not effective. An alternative is to consider some sub- 
guideline treatment bundles as having a lower probability of being effica- 
cious than are those meeting guideline criteria, and therefore to assign the 
subguideline episodes a lower quantity weight. Together with a group of 
clinicians and psychiatric researchers, we  are currently initiating an effort 
to more completely define the specific depression treatment production 
function. 
Second, we have adhered rather closely to the notion of defining output 
in terms of episodes of acute phase treatment. This involves a somewhat 
arbitrary delineation of an output that often does not correspond well to 
the reality of clinical practice. Because depression is often a chronic recur- 
ring illness, continuation and maintenance phase care are part of the over- 
all treatment of the disorder. Unfortunately, because the bulk of clinical 
research has focused on the acute phase of treatment, our links to out- 500  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
comes were tied to a somewhat imperfect characterization of  care. It is 
therefore important to more completely specify treatment in this context. 
Finally, and perhaps most surprisingly, all of our results point to the 
fact that given a budget for treatment of depression, much more could be 
accomplished in 1995 than in 1991. That is, real prices of care have fallen. 
This runs counter to most public and expert perceptions. The implications 
for interpreting spending changes are enormous. For years the view  has 
been that spending increases on mental health care (of which depression 
is 50 percent in private insurance) was due to provision of increasing low 
benefit services and higher payments to providers. Our results point to a 
different story where spending increases are due to a larger number  of 
“effective” treatments being provided. These treatments represent a shift 
toward new treatment technologies that are provided under a new set of 
organizational arrangements. 
Appendix 
Table 12A.1  Aggregate Producer (“Supply”)  Price Indexes Calculated Using 
Broader Standard of Care Definitions 
Price Index  1991  1992  1993  1994  1995 
~~~~  ~  ~  ~ 
Fixed weights 
Laspeyres  1.000  1.015  0.984  0.929  0.997 
Paasche  1.000  1.029  1.000  0.968  1.010 
Laspeyres  1.000  1.015  0.981  0.941  0.985 
Paasche  1.000  1.017  0.986  0.952  0.993 
Fisher ideal  1.000  1.016  0.983  0.946  0.989 
Tornqvist  1.000  1.016  0.983  0.946  0.988 
Chained weights 
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Comment  Darrel A. Regier 
This paper by Berndt, Busch, and Frank offers a new and important para- 
digm for evaluating the costs of providing and obtaining mental health 
treatment services in a rapidly changing “defacto mental health service 
system” (Regier et al. 1993). It is an ambitious effort to use the Bureau of 
Labor Statistics (BLS) Producer Price Index (PPI) and Consumer Price 
Index (CPI) conventions to describe market changes in the cost of treating 
major depression over a five-year time frame (1991-1995).  The authors 
attempt to go beyond the usual CPI approach of  assessing the average 
price of a “fixed market basket of goods and services,” such as the average 
cost of a mental health visit, bed-day, or medicatiodday, to examining the 
cost of an episode of care that meets American Psychiatric Association 
treatment-guideline  standards  for major  depressive disorder  in  adults. 
(APA 1993). Although such an approach to assessing “the average costs 
of the complete treatment of  individual illnesses” was recommended  as 
early as 1962 by Scitovsky, very few have advanced beyond pricing health 
care inputs to obtaining the price of health care outcomes. 
Within the mental health field, there have been very few published stud- 
ies that attempt to assess the cost effectiveness of mental disorder treat- 
ments by using comparative treatment outcomes in the analysis. A notable 
exception is the study by Rogers et al. (1993), which evaluated the relative 
cost of treatment outcomes of depression in different service systems. In 
this landmark study, psychiatrists in an HMO practice offered ostensibly 
less expensive treatment for depression with fewer visits and a lower use 
of antidepressant medications than were provided for comparable patients 
in fee-for-service settings. However, when outcomes were factored into the 
cost estimates, the more intensive treatment was shown to be a more cost- 
effective approach. 
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With this background in mind,  the authors are careful to  review the 
epidemiological literature to assess the potential true prevalence of major 
depressive disorder in contrast to the treated prevalence reported for the 
MEDSTAT population  used in this paper. There is a significant gap be- 
tween the reported  10.3 percent annual prevalence of major depression 
cited from the National Comorbidity Survey (Kessler et al. 1994) and the 
18,920 episodes of acute care for major depression from 428,168 enrollees 
during the five-year study period. If every episode represented a different 
patient, this would represent only 4.4 percent of the population or an aver- 
age of less than 1 percent of the population receiving such care each year. 
The  obvious  discrepancy  between  ostensible prevalence  and treatment 
rates raises important questions about the clinical significance of the prev- 
alence rates (Regier et al. 1998), barriers to treatment  demand, assess- 
ments of “medical necessity” for care (Regier et al. 2000), and the cost of 
failure to provide treatment  (Rupp  1995). However, such larger public 
health issues remain somewhat outside the scope of this important paper. 
The authors do take advantage of a large volume of clinical trials litera- 
ture on treatment efficacy and the synthesis of this information into treat- 
ment guideline standards. They are able to use these well-accepted stan- 
dards to define “treatment bundles” of specific antidepressant medications 
and psychotherapies, which are considered comparable in effectiveness for 
either severe or less severe forms of depression. Since only administrative 
data sets are available for this study, these treatment bundles of known ef- 
fectiveness (under ideal research conditions as expressed in treatment guide- 
lines) serve as outcome proxies for price comparisons that are attempting 
to take episode outcomes into account. Seven different bundles included 
psychotherapy  or  antidepressant  medication  treatment  either  alone  or 
in various combinations for treatment guideline-determined duration and 
level of intensity or dose. 
The authors note that the proportion of guideline-compatible treatment 
episodes rose substantially over the five years of experience with the treat- 
ment system from 35 percent in 1991 to 56 percent in 1995. The quantities 
and prices of each treatment bundle were assessed with the finding that the 
average supply price (PPI equivalent) of the treatment bundles decreased 
slightly over the five-year period even as there were major  shifts in the 
relative proportions of treatment modalities over this time period. In con- 
trast, the consumer demand price (CPI equivalent) increased by more than 
22  percent  in  a  single year  (1994-1995)  as a  result  of  benefit  design 
changes which increased copayments and deductibles for mental  health 
treatment.  The net conclusion from these findings is  that  the improved 
compliance with treatment guideline standards in the face of supply price 
reductions implies a gain in production efficiency within the mental health 
system. However, the increase in  consumer costs to control  the “moral 
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has other equity implications. The rise in political support for legislation 
which would mandate parity in benefits for mental and physical disorders 
has been propelled by  the perceived inequity that is  reflected in the re- 
ported rise in CPI-equivalent costs for treatment of mental disorders (Zu- 
vekas, Banthin, and Selden 1998; National Advisory Mental Health Coun- 
cil 1998). 
The authors are to be commended for their creative analytic approaches 
to mainstreaming health services in general and mental health services in 
particular into the PPI and CPI framework. The availability of such a well- 
respected economic framework for evaluating the production of  mental 
health  services could be  of  considerable value to policymakers in  their 
assessment of the relative cost and value of investing greater resources in 
mental health services, research, and system development. 
As  a practicing clinical psychiatrist, I am impressed by  the care with 
which the authors have reviewed the clinical treatment literature and have 
attempted to model the practice guidelines with administrative claims data 
sets. They also have recognized the limitations of these claims data for 
capturing the full picture of treatment  for major depression, which has 
both acute treatment requirements for all, and chronic maintenance treat- 
ment requirements for many others. However, the shift in treatment styles 
from a predominance of  psychotherapy alone to antidepressant medica- 
tion alone or in combination during this time frame does have a clear face 
validity. The shift to the newer SSRI antidepressant medications is  also 
adequately mirrored in this data set. However, before this model is ready 
for prime time implementation as a component of  published PPIs and 
CPIs from the BLS, it would be important to have a few replications and 
refinements. 
As an epidemiologist with a great deal of interest in the policy applica- 
tions of such research data, I am impressed by  the potential benefits of 
obtaining mental disorder prevalence rates which would more accurately 
reflect the need for specific types of treatment  (e.g., treatment bundles). 
The current movement in psychopathology assessment is to obtain more 
specific measures of clinically significant impairment and symptom levels 
(routinely used in treatment efficacy studies) in addition to existing diag- 
nostic criteria. If such fine-grained diagnostic criteria could be reflected in 
epidemiological studies as well  as in the  diagnostic codes recorded in 
claims records, the value of the indexes proposed in this paper could obvi- 
ously be advanced. 
Although many other health policy issues are touched on by  this paper, 
including the issue of the optimal cost-sharing for patients seeking mental 
health services, the most important policy emphasis is the focus on out- 
come or quality of care rather than simply cost of care. With the current 
managed care industry competition “race to the bottom” on per-member- 
per-month  costs, it  is  most important to have cost measures which  are 508  Ernst R. Berndt, Susan H. Busch, and Richard G. Frank 
adjusted for quality as determined by  the outcome of treatment episodes. 
It is somewhat unexpected to have economists leading the way by identi- 
fying methods which would tilt the industry toward quality competition 
when clinicians and clinical research investigators have been so slow to 
respond to this challenge. I hope that the obvious benefits of collaboration 
between  economists,  clinical  investigators,  epidemiologists,  and  other 
health services researchers will result in refining the outstanding work rep- 
resented in this paper to the point where it will become a standard eco- 
nomic index for the field. 
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